VALBIOTIS (EPA:ALVAL) | WebDisclosure

Basculer en Français

10411	Companies
217812	Keywords
147362	Articles
115250	Press releases

Home
Companies
VALBIOTIS

PRESS RELEASE

published on 04/26/2024 at 07:30, 2 years ago

Valbiotis publie ses comptes annuels 2023
Valbiotis publie ses comptes annuels 2023 avec une solide trésorerie de plus de 25 M€ à fin 2023. Succès clinique de l'étude sur TOTUM•63. Lancement commercial de Valbiotis®PRO Cholestérol en vue. Structuration industrielle et commerciale accélérée

Valbiotis Trésorerie Comptes Annuels 2023 TOTUM•63 Valbiotis®PRO Cholestérol
PRESS RELEASE

published on 04/26/2024 at 07:30, 2 years ago

Valbiotis publishes its annual accounts 2023
Valbiotis publishes annual accounts 2023 with solid cash position of over €25 million. Highlights include successful TOTUM•63 study and upcoming market launches

Cash Position Valbiotis Annual Accounts TOTUM•63 Market Launches
BRIEF

published on 04/08/2024 at 17:45, 2 years 1 month ago

Valbiotis annonce son nombre de droits de vote et d'actions pour mars 2024

Euronext Growth Paris Droits De Vote Capital Social Transparence Valbiotis
BRIEF

published on 04/08/2024 at 17:45, 2 years 1 month ago

Valbiotis announces its number of voting rights and shares for March 2024

Euronext Growth Paris Share Capital Voting Rights Transparency Valbiotis
PRESS RELEASE

published on 04/08/2024 at 17:40, 2 years 1 month ago

Valbiotis : Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social - Mars 2024
Valbiotis publie ses informations mensuelles sur le nombre total de droits de vote et d'actions en mars 2024, conformément aux règles de l'AMF. L'entreprise se spécialise dans les compléments alimentaires pour la prévention des troubles métaboliques

Droits De Vote Actions Valbiotis Compléments Alimentaires Prévention Troubles Métaboliques
BRIEF

published on 04/03/2024 at 08:35, 2 years 1 month ago

Valbiotis lance un complément alimentaire innovant pour lutter contre l'hypercholestérolémie

Valbiotis Santé Cardiovasculaire Complément Alimentaire Hypercholestérolémie Lipidrive
BRIEF

published on 04/03/2024 at 08:35, 2 years 1 month ago

Valbiotis launches an innovative food supplement to fight hypercholesterolemia

Valbiotis Cardiovascular Health Lipidrive Hypercholesterolemia Dietary Supplement
PRESS RELEASE

published on 04/03/2024 at 08:30, 2 years 1 month ago

Valbiotis commercialisera dès mai sur le marché français son complément alimentaire 100% naturel pour la prise en charge de l’hypercholestérolémie
Valbiotis commercialisera dès mai en France son complément alimentaire 100% naturel pour l'hypercholestérolémie. Une solution non médicamenteuse testée cliniquement

Valbiotis Complément Alimentaire Hypercholestérolémie Lipidrive Études Cliniques
PRESS RELEASE

published on 04/03/2024 at 08:30, 2 years 1 month ago

Valbiotis to launch its 100% natural dietary supplement for the management of hypercholesterolemia on the French market in May
Valbiotis to launch its 100% natural dietary supplement for the management of hypercholesterolemia on the French market in May. The supplement, Valbiotis®PRO Cholestérol, with the patented active substance Lipidrive®, aims at tackling mild to moderate LDL hypercholesterolemia

Valbiotis French Market Lipidrive Hypercholesterolemia Dietary Supplement
BRIEF

published on 03/07/2024 at 17:45, 2 years 2 months ago

VALBIOTIS SA annonce ses chiffres de droits de vote pour Février 2024

Marché Financier Droits De Vote Capital Social Transparence Valbiotis

Accesswire

Published on 05/16/2026 at 01:15, 15 hours 35 minutes ago

Findev Inc. Announces a New Member of the Board of Directors
Published on 05/16/2026 at 01:00, 15 hours 50 minutes ago

Arctic Fox Adopts Semi-Annual Reporting
Published on 05/16/2026 at 00:00, 16 hours 50 minutes ago

Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate
Published on 05/15/2026 at 23:10, 17 hours 40 minutes ago

Golden Minerals Reports First Quarter 2026 Financial Results
Published on 05/15/2026 at 23:00, 17 hours 50 minutes ago

Jericho Energy Ventures Announces Transition to Semi-Annual Reporting to Enhance Efficiency

View all ACCESSWIRE

EQS Group

Published on 05/16/2026 at 16:08, 41 minutes ago

The publication of the audited financial statements for 2025 will be postponed to 12 June 2026 – management does not expect any significant changes to the figures already published
Published on 05/15/2026 at 20:10, 20 hours 40 minutes ago

CPIPG Communication Concerning Voluntary Offer on NEXT RE Shares – Provisional Results Announcement
Published on 05/15/2026 at 18:30, 22 hours 20 minutes ago

Designated Person Notifications
Published on 05/15/2026 at 18:30, 22 hours 20 minutes ago

Designated Person Notifications
Published on 05/15/2026 at 18:10, 22 hours 39 minutes ago

Virtual Science AI launches first AI-driven competitor activity tracking platform to support pharma asset launch success

Les Echos

Published on 05/15/2026 at 15:08, 1 day 1 hour ago

Notice of exercise of early redemption option of the subordinated note ISIN : FR0010203026
Published on 05/15/2026 at 15:00, 1 day 1 hour ago

Exercice de l’option de remboursement de l'instrument subordonné FR0010203026
Published on 05/15/2026 at 10:09, 1 day 6 hours ago

Groupe Crit : Modalités de mise à disposition des documents préparatoires à l’Assemblée Générale Mixte du 05 juin 2026.
Published on 05/14/2026 at 09:03, 2 days 7 hours ago

Coup d'envoi pour les carrières dans l'esport : 65% de la population mondiale réclame plus de formations et de parcours professionnels pour le jeu vidéo de compétition
Published on 05/13/2026 at 18:02, 2 days 22 hours ago

ALTAREA : Assemblée Générale Mixte du 4 juin 2026 MODALITES DE MISE A DISPOSITION DES DOCUMENTS PREPARATOIRES

View all LES ECHOS COMFI WIRE